FIELD: medicine, oncology.
SUBSTANCE: the present innovation deals with inhibiting the growth of host's cerebral tumors. It deals with introducing therapeutically efficient quantity of integrin αv antagonists being cyclo(Arg-Gly-Asp-D-Phe-[N-Me]-Val). The innovation enables to considerably inhibit cerebral oncogenesis in vivo, moreover, despite antiangiogenesis, due to induction of direct lethality of tumor cells.
EFFECT: higher efficiency of inhibition.
9 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
| METHODS AND COMPOSITION USEFUL FOR ANGIOGENESIS INHIBITION | 1995 |
|
RU2162712C2 |
| VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
| METHODS AND COMPOSITIONS USED FOR INHIBITING ANGIOGENESIS | 1997 |
|
RU2194528C2 |
| COMBINED THERAPY USING INHIBITORS OF TYROSINE KINASE RECEPTORS AND INHIBITORS OF ANGIOGENESIS | 2001 |
|
RU2292904C2 |
| METHOD OF TREATMENT OF TUMORS | 2003 |
|
RU2323737C2 |
| TECHNIQUES AND COMPOSITIONS USED TO INHIBIT αβ-CAUSED ANGIOGENESIS | 1997 |
|
RU2195312C2 |
| POLYPEPTIDE FOR INHIBITING MIGRATION AND INVASION OF PROSTATE CANCER | 2019 |
|
RU2711085C1 |
| PHARMACEUTICAL COMPOSITIONS AIMED AT Erb-B1 RECEPTORS | 2003 |
|
RU2354402C2 |
| ANGIOPOIETIC ANGIOPOIETIN-LIKE PROTEIN 4 INHIBITORS, IN COMBINATIONS AND APPLICATION | 2005 |
|
RU2392966C2 |
